Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc. (0JQ2.L) Stock Overview
Explore Kala Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
42.5M
P/E Ratio
-1.15
EPS (TTM)
N/A
ROE
-3.69%
0JQ2.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kala Pharmaceuticals, Inc. (0JQ2.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 73.27, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $2.68.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.15 and a market capitalization of 42.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Todd Bazemore
38
1167 Massachusetts Avenue, Arlington, MA
2018